Basirli H, Ates N, Seyrantepe V
Mol Biol Rep. 2025; 52(1):282.
PMID: 40042748
DOI: 10.1007/s11033-025-10380-y.
Inci O, Seyrantepe V
Metab Brain Dis. 2025; 40(3):133.
PMID: 40019557
PMC: 11870964.
DOI: 10.1007/s11011-025-01553-6.
Platt N, Shepherd D, Smith D, Smith C, Wallom K, Luqmani R
Cells. 2025; 14(1.
PMID: 39791736
PMC: 11720672.
DOI: 10.3390/cells14010035.
Lopez M, Wendt D, Lawrence R, Gong K, Ong H, Yip B
PLoS One. 2025; 20(1):e0315005.
PMID: 39752451
PMC: 11698352.
DOI: 10.1371/journal.pone.0315005.
Tsourmas K, Butler C, Kwang N, Sloane Z, Dykman K, Maloof G
bioRxiv. 2024; .
PMID: 39484433
PMC: 11526954.
DOI: 10.1101/2024.10.21.619538.
Hexosaminidase B-driven cancer cell-macrophage co-dependency promotes glycolysis addiction and tumorigenesis in glioblastoma.
Zhu C, Chen X, Liu T, Cheng L, Cheng W, Cheng P
Nat Commun. 2024; 15(1):8506.
PMID: 39353936
PMC: 11445535.
DOI: 10.1038/s41467-024-52888-0.
Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.
Metovic J, Li Y, Gong Y, Eichler F
Neurotherapeutics. 2024; 21(4):e00443.
PMID: 39276676
PMC: 11418141.
DOI: 10.1016/j.neurot.2024.e00443.
Characterization of a phenotypically severe animal model for human AB-Variant GM2 gangliosidosis.
Deschenes N, Cheng C, Khanal P, Quinville B, Ryckman A, Mitchell M
Front Mol Neurosci. 2023; 16:1242814.
PMID: 38098938
PMC: 10720325.
DOI: 10.3389/fnmol.2023.1242814.
Lipid Structure Matters in Lysosomal Storage Disease.
Sandhoff R
J Lipid Res. 2023; 64(12):100476.
PMID: 37972730
PMC: 10757020.
DOI: 10.1016/j.jlr.2023.100476.
Targeting GM2 Ganglioside Accumulation in Dementia: Current Therapeutic Approaches and Future Directions.
Kumar S, Panda S
Curr Mol Med. 2023; 24(11):1329-1345.
PMID: 37877564
DOI: 10.2174/0115665240264547231017110613.
A comparative analysis of microglial inducible Cre lines.
Faust T, Feinberg P, OConnor C, Kawaguchi R, Chan A, Strasburger H
Cell Rep. 2023; 42(9):113031.
PMID: 37635351
PMC: 10591718.
DOI: 10.1016/j.celrep.2023.113031.
Life-Limiting Peripheral Organ Dysfunction in Feline Sandhoff Disease Emerges after Effective CNS Gene Therapy.
Johnson A, McCurdy V, Gray-Edwards H, Maguire A, Cochran J, Gross A
Ann Neurol. 2023; 94(5):969-986.
PMID: 37526361
PMC: 10718573.
DOI: 10.1002/ana.26756.
Single Systemic Administration of a Gene Therapy Leading to Disease Treatment in Metachromatic Leukodystrophy Knock-Out Mice.
St Martin T, Seabrook T, Gall K, Newman J, Avila N, Hayes A
J Neurosci. 2023; 43(19):3567-3581.
PMID: 36977578
PMC: 10184740.
DOI: 10.1523/JNEUROSCI.1829-22.2023.
A comparative analysis of microglial inducible Cre lines.
Faust T, Feinberg P, OConnor C, Kawaguchi R, Chan A, Strasburger H
bioRxiv. 2023; .
PMID: 36711492
PMC: 9881995.
DOI: 10.1101/2023.01.09.523268.
Glb1 knockout mouse model shares natural history with type II GM1 gangliosidosis patients.
Nicoli E, Huebecker M, Han S, Garcia K, Munasinghe J, Lizak M
Mol Genet Metab. 2023; 138(2):107508.
PMID: 36709532
PMC: 10617618.
DOI: 10.1016/j.ymgme.2023.107508.
Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders.
Cachon-Gonzalez M, Zhao C, Franklin R, Cox T
Hum Mol Genet. 2022; 32(8):1361-1379.
PMID: 36519759
PMC: 10077509.
DOI: 10.1093/hmg/ddac299.
Neuronal Ganglioside and Glycosphingolipid (GSL) Metabolism and Disease : Cascades of Secondary Metabolic Errors Can Generate Complex Pathologies (in LSDs).
Sandhoff R, Sandhoff K
Adv Neurobiol. 2022; 29:333-390.
PMID: 36255681
DOI: 10.1007/978-3-031-12390-0_12.
Establishment of blood glycosidase activities and their excursions in sepsis.
Haslund-Gourley B, Aziz P, Heithoff D, Restagno D, Fried J, Ilse M
PNAS Nexus. 2022; 1(3):pgac113.
PMID: 35967980
PMC: 9364217.
DOI: 10.1093/pnasnexus/pgac113.
Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosis.
Sala D, Ornaghi F, Morena F, Argentati C, Valsecchi M, Alberizzi V
Mol Ther Methods Clin Dev. 2022; 25:170-189.
PMID: 35434178
PMC: 8983315.
DOI: 10.1016/j.omtm.2022.03.011.
Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients.
Welford R, Farine H, Steiner M, Garzotti M, Dobrenis K, Sievers C
Mol Genet Metab Rep. 2022; 30:100843.
PMID: 35242574
PMC: 8856936.
DOI: 10.1016/j.ymgmr.2022.100843.